Valneva SE (VALN) News & Overview - Discounting Cash Flows
VALN
Valneva SE
VALN (NASDAQ)

General Overview

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Sector & Industry Healthcare / Biotechnology
Website https://valneva.com
IPO date May 5, 2021

VALN Latest News

Other Identifiers
CIK0001836564
ISINUS92025Y1038
CUSIP92025Y103
Open5.6596
Previous Close5.72
Volume5.96 Thou.
Average Volume76.03 Thou.
Day’s Range5.6567 – 6.0603
52 Week Range3.62-8.661
MA (50)6.24622
MA (200)5.85069
Market Cap494 Mil.
Shares Out.85.03 Mil.
Earnings DateAug 12, 2025
Beta
Last Dividend
EPS
PE
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us